Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (wegener's)

Gunnar Tomasson, Maarten Boers, Michael Walsh, Michael LaValley, David Cuthbertson, Simon Carette, John C. Davis, Gary S. Hoffman, Nader A. Khalidi, Carol A. Langford, Carol A. McAlear, W. Joseph McCune, Paul A. Monach, Philip Seo, Ulrich Specks, Robert Spiera, E. William St.Clair, John H. Stone, Steven R Ytterberg, Peter A. Merkel

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

To assess a generic measure of health-related quality of life (HRQOL) as an outcome measure in granulomatosis with polyangiitis (Wegener's) (GPA). Methods. Subjects were participants in the Wegener's Granulomatosis Etanercept Trial (WGET) or the Vasculitis Clinical Research Consortium Longitudinal Study (VCRC-LS). HRQOL was assessed with the Short Form 36 (SF-36) health survey that includes physical and mental component summary scores (PCS and MCS, respectively). Disease activity was assessed with the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG). Results. The data from 180 subjects in the WGET (median followup 2.3 years, mean number of visits 10) and 237 subjects in the VCRC-LS (median followup 2.0 years, mean number of visits 8) were analyzed. A 1 unit increase in the BVAS/WG corresponded to a 1.15 unit (95% confidence interval [95% CI] 1.02, 1.29) decrease for the PCS and a 0.93 (95% CI 0.78, 1.07) decrease for the MCS in the WGET, and to a 1.16 unit decrease for the PCS (95% CI 0.94, 1.39) and a 0.79 unit decrease for the MCS (95% CI 0.51, 1.39) in the VCRC-LS. In both arms of the WGET study, SF-36 measures improved rapidly during the first 6 weeks of treatment followed by gradual improvement among patients achieving sustained remission (0.5 improvement in PCS per 3 months), but worsened slightly (0.03 decrease in PCS every 3 months) among patients not achieving sustained remission (P - 0.005). Conclusion. HRQOL, as measured by the SF-36, is reduced among patients with GPA. SF-36 measures are modestly associated with other disease outcomes and discriminate between disease states of importance in GPA.

Original languageEnglish (US)
Pages (from-to)273-279
Number of pages7
JournalArthritis Care and Research
Volume64
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Granulomatosis with Polyangiitis
Vasculitis
Quality of Life
Outcome Assessment (Health Care)
Confidence Intervals
Longitudinal Studies
Research
Health Surveys
Etanercept

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Tomasson, G., Boers, M., Walsh, M., LaValley, M., Cuthbertson, D., Carette, S., ... Merkel, P. A. (2012). Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (wegener's). Arthritis Care and Research, 64(2), 273-279. https://doi.org/10.1002/acr.20649

Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (wegener's). / Tomasson, Gunnar; Boers, Maarten; Walsh, Michael; LaValley, Michael; Cuthbertson, David; Carette, Simon; Davis, John C.; Hoffman, Gary S.; Khalidi, Nader A.; Langford, Carol A.; McAlear, Carol A.; McCune, W. Joseph; Monach, Paul A.; Seo, Philip; Specks, Ulrich; Spiera, Robert; St.Clair, E. William; Stone, John H.; Ytterberg, Steven R; Merkel, Peter A.

In: Arthritis Care and Research, Vol. 64, No. 2, 02.2012, p. 273-279.

Research output: Contribution to journalArticle

Tomasson, G, Boers, M, Walsh, M, LaValley, M, Cuthbertson, D, Carette, S, Davis, JC, Hoffman, GS, Khalidi, NA, Langford, CA, McAlear, CA, McCune, WJ, Monach, PA, Seo, P, Specks, U, Spiera, R, St.Clair, EW, Stone, JH, Ytterberg, SR & Merkel, PA 2012, 'Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (wegener's)', Arthritis Care and Research, vol. 64, no. 2, pp. 273-279. https://doi.org/10.1002/acr.20649
Tomasson, Gunnar ; Boers, Maarten ; Walsh, Michael ; LaValley, Michael ; Cuthbertson, David ; Carette, Simon ; Davis, John C. ; Hoffman, Gary S. ; Khalidi, Nader A. ; Langford, Carol A. ; McAlear, Carol A. ; McCune, W. Joseph ; Monach, Paul A. ; Seo, Philip ; Specks, Ulrich ; Spiera, Robert ; St.Clair, E. William ; Stone, John H. ; Ytterberg, Steven R ; Merkel, Peter A. / Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (wegener's). In: Arthritis Care and Research. 2012 ; Vol. 64, No. 2. pp. 273-279.
@article{50020e27fe984e54b9cac6b4e2d05c54,
title = "Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (wegener's)",
abstract = "To assess a generic measure of health-related quality of life (HRQOL) as an outcome measure in granulomatosis with polyangiitis (Wegener's) (GPA). Methods. Subjects were participants in the Wegener's Granulomatosis Etanercept Trial (WGET) or the Vasculitis Clinical Research Consortium Longitudinal Study (VCRC-LS). HRQOL was assessed with the Short Form 36 (SF-36) health survey that includes physical and mental component summary scores (PCS and MCS, respectively). Disease activity was assessed with the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG). Results. The data from 180 subjects in the WGET (median followup 2.3 years, mean number of visits 10) and 237 subjects in the VCRC-LS (median followup 2.0 years, mean number of visits 8) were analyzed. A 1 unit increase in the BVAS/WG corresponded to a 1.15 unit (95{\%} confidence interval [95{\%} CI] 1.02, 1.29) decrease for the PCS and a 0.93 (95{\%} CI 0.78, 1.07) decrease for the MCS in the WGET, and to a 1.16 unit decrease for the PCS (95{\%} CI 0.94, 1.39) and a 0.79 unit decrease for the MCS (95{\%} CI 0.51, 1.39) in the VCRC-LS. In both arms of the WGET study, SF-36 measures improved rapidly during the first 6 weeks of treatment followed by gradual improvement among patients achieving sustained remission (0.5 improvement in PCS per 3 months), but worsened slightly (0.03 decrease in PCS every 3 months) among patients not achieving sustained remission (P - 0.005). Conclusion. HRQOL, as measured by the SF-36, is reduced among patients with GPA. SF-36 measures are modestly associated with other disease outcomes and discriminate between disease states of importance in GPA.",
author = "Gunnar Tomasson and Maarten Boers and Michael Walsh and Michael LaValley and David Cuthbertson and Simon Carette and Davis, {John C.} and Hoffman, {Gary S.} and Khalidi, {Nader A.} and Langford, {Carol A.} and McAlear, {Carol A.} and McCune, {W. Joseph} and Monach, {Paul A.} and Philip Seo and Ulrich Specks and Robert Spiera and St.Clair, {E. William} and Stone, {John H.} and Ytterberg, {Steven R} and Merkel, {Peter A.}",
year = "2012",
month = "2",
doi = "10.1002/acr.20649",
language = "English (US)",
volume = "64",
pages = "273--279",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (wegener's)

AU - Tomasson, Gunnar

AU - Boers, Maarten

AU - Walsh, Michael

AU - LaValley, Michael

AU - Cuthbertson, David

AU - Carette, Simon

AU - Davis, John C.

AU - Hoffman, Gary S.

AU - Khalidi, Nader A.

AU - Langford, Carol A.

AU - McAlear, Carol A.

AU - McCune, W. Joseph

AU - Monach, Paul A.

AU - Seo, Philip

AU - Specks, Ulrich

AU - Spiera, Robert

AU - St.Clair, E. William

AU - Stone, John H.

AU - Ytterberg, Steven R

AU - Merkel, Peter A.

PY - 2012/2

Y1 - 2012/2

N2 - To assess a generic measure of health-related quality of life (HRQOL) as an outcome measure in granulomatosis with polyangiitis (Wegener's) (GPA). Methods. Subjects were participants in the Wegener's Granulomatosis Etanercept Trial (WGET) or the Vasculitis Clinical Research Consortium Longitudinal Study (VCRC-LS). HRQOL was assessed with the Short Form 36 (SF-36) health survey that includes physical and mental component summary scores (PCS and MCS, respectively). Disease activity was assessed with the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG). Results. The data from 180 subjects in the WGET (median followup 2.3 years, mean number of visits 10) and 237 subjects in the VCRC-LS (median followup 2.0 years, mean number of visits 8) were analyzed. A 1 unit increase in the BVAS/WG corresponded to a 1.15 unit (95% confidence interval [95% CI] 1.02, 1.29) decrease for the PCS and a 0.93 (95% CI 0.78, 1.07) decrease for the MCS in the WGET, and to a 1.16 unit decrease for the PCS (95% CI 0.94, 1.39) and a 0.79 unit decrease for the MCS (95% CI 0.51, 1.39) in the VCRC-LS. In both arms of the WGET study, SF-36 measures improved rapidly during the first 6 weeks of treatment followed by gradual improvement among patients achieving sustained remission (0.5 improvement in PCS per 3 months), but worsened slightly (0.03 decrease in PCS every 3 months) among patients not achieving sustained remission (P - 0.005). Conclusion. HRQOL, as measured by the SF-36, is reduced among patients with GPA. SF-36 measures are modestly associated with other disease outcomes and discriminate between disease states of importance in GPA.

AB - To assess a generic measure of health-related quality of life (HRQOL) as an outcome measure in granulomatosis with polyangiitis (Wegener's) (GPA). Methods. Subjects were participants in the Wegener's Granulomatosis Etanercept Trial (WGET) or the Vasculitis Clinical Research Consortium Longitudinal Study (VCRC-LS). HRQOL was assessed with the Short Form 36 (SF-36) health survey that includes physical and mental component summary scores (PCS and MCS, respectively). Disease activity was assessed with the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG). Results. The data from 180 subjects in the WGET (median followup 2.3 years, mean number of visits 10) and 237 subjects in the VCRC-LS (median followup 2.0 years, mean number of visits 8) were analyzed. A 1 unit increase in the BVAS/WG corresponded to a 1.15 unit (95% confidence interval [95% CI] 1.02, 1.29) decrease for the PCS and a 0.93 (95% CI 0.78, 1.07) decrease for the MCS in the WGET, and to a 1.16 unit decrease for the PCS (95% CI 0.94, 1.39) and a 0.79 unit decrease for the MCS (95% CI 0.51, 1.39) in the VCRC-LS. In both arms of the WGET study, SF-36 measures improved rapidly during the first 6 weeks of treatment followed by gradual improvement among patients achieving sustained remission (0.5 improvement in PCS per 3 months), but worsened slightly (0.03 decrease in PCS every 3 months) among patients not achieving sustained remission (P - 0.005). Conclusion. HRQOL, as measured by the SF-36, is reduced among patients with GPA. SF-36 measures are modestly associated with other disease outcomes and discriminate between disease states of importance in GPA.

UR - http://www.scopus.com/inward/record.url?scp=84858044570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858044570&partnerID=8YFLogxK

U2 - 10.1002/acr.20649

DO - 10.1002/acr.20649

M3 - Article

C2 - 21954229

AN - SCOPUS:84858044570

VL - 64

SP - 273

EP - 279

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 2

ER -